Inflammatory Bowel Disease Treatment Market Analysis

Global Inflammatory Bowel Disease Treatment Market Overview

Inflammatory Bowel Disease Treatment Market Size was valued at USD 22.36 Billion in 2023. The Global Inflammatory Bowel Disease Treatment industry is projected to grow from USD 24.00 Billion in 2024 to USD 38.92 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.52% during the forecast period (2024 - 2032).

Crohn's disease and ulcerative colitis are becoming more common, and Government funding for Inflammatory Bowel Disease treatment therapy research and medical technology advancements. These are just a few of the market drivers that are driving the market.

Technological developments, including using single-cell RNA sequencing to manage inflammatory bowel disease, are advantageous to healthcare professionals. High-dimensional technologies, such as mass cytometry and single-cell RNA sequencing, have been used for intestinal tissues taken from patients with Crohn's disease or ulcerative colitis. In the digestive tract, Crohn's disease produces pain and swelling. The small and upper large intestines are typically affected. Additionally, ulcerative colitis results in ulcers and swelling in the large intestine. Mucosal inflammation, which causes edema, hemorrhaging ulcers, and electrolyte deficits, is a constant symptom of ulcerative colitis. These specific forms of inflammatory bowel disorder affect people with an unsuitable immune reaction to the intestinal flora. The persistent inflammation of these illnesses results in gastrointestinal tract damage.

Inflammatory bowel disease is genetically predisposed, and those with it are more likely to develop cancer than those without it. The discovery of new treatments, the optimization of specific medications, and the prevention of the disease are all advantages of the single-cell RNA sequencing study utilized to comprehend the molecular foundation of the disease. Globally, the prevalence of Crohn's disease and ulcerative colitis is increasing for several causes, including socioeconomic and environmental shifts in lifestyle. Additionally, a greater disease diagnosis rate and suitable reimbursement policy in developed nations help the market's growth, given the growing emphasis on early disease diagnosis.

This raised the need for inflammatory bowel disease therapy medications, including TNF inhibitors, JAK inhibitors, IL inhibitors, and others available, and the number of individuals receiving treatment for IBD. The industry is also anticipated to rise due to improved reimbursement policies in established and developing nations that cover expensive IBD treatment solutions. On the other side, the retail pharmacy sector dominated the market for treating inflammatory bowel disease, which had the second-largest share. High-dimensional technologies, such as mass cytometry or single-cell RNA sequencing, have been used on the intestinal tissues taken from patients with Crohn's disease, among others.

In the month of March 2024, Crohn's & Colitis Foundation invested in three firms as part of IBD Ventures program’s 2023 financing round. In order to hasten the development of remission rates and health restoration in people with inflammatory bowel disease (IBD), IBD Ventures supports product-oriented research and development directly on the pathogeneses.

In March 2024, Crohn’s & Colitis UK launched a medication tool that aims at understanding other possible options of therapy available for patients.

Subsequently, concerning those handling Inflammatory Bowel Disease (IBD), great news happened in February 2024. The project was jointly conducted by EnLiSense CCM, financed by the Crohn's & Colitis Foundation together with the Mount Sinai School of Medicine. It delivered optimistic results for the innovative monitoring device named IBD Aware. This innovative wearable uses sweat-based technology and can thus become the first non-invasive continuous IBD monitoring solution. The two major tests carried out in February 2024 revealed the high potential of IBD Aware, hence brightening prospects for more affordable and efficient ways to watch over this malady.

April 2023: Prometheus Biosciences, Inc., a clinical-stage biotechnology firm, has been acquired by Merck & Co., Inc., whose aim was to get late-development product PRA023 owned by Prometheus currently undergoing clinical study for ulcerative colitis and Crohn’s disease along with other autoimmune diseases.

As an example, EMA approved Skyrizi IV to treat moderately-to-severely active Crohn’s disease in November 2022.

On its part, Athos Therapeutics declared plans for partnership-based research work with Lahey Hospital and Medical Center in Burlington, Massachusetts, focused on precision medicine for IBD and ulcerative colitis during July 2022.

May 2022 marked the release of The Indian Council of Medical Research (ICMR) IBD NutriCare App, which enhances healthcare provision for patients with inflammatory bowel disease (IBD).

Inflammatory Bowel Disease Treatment Market Trends

• Rising Disease Prevalence and Strong Focus on R&D for Inflammatory Bowel Disease Treatment will boost market growth

Healthcare practitioners are benefiting from technological advancements like the use of single-cell RNA sequencing in the treatment of Inflammatory Bowel Disease treatment. The intestinal tissues obtained from individuals with Crohn's disease or ulcerative colitis have been subjected to high-dimensional technologies, including single-cell RNA sequencing and mass cytometry. The creation of innovative therapeutic strategies, the optimization of specific medications, and the prevention of the disease are some advantages of the single-cell RNA sequencing study used to comprehend the molecular foundation of the disease. To identify tissue and immune cell properties in people with or without ulcerative colitis, for instance, The University of California and V.A. San Diego Healthcare System (VASDHS) applied transcriptome and antigen receptor sequencing techniques in August 2020. These technological developments offer a novel perspective on immune cell networks in health and illness. Patients with ulcerative colitis and Crohn's disease can benefit from their tailored medication approach. Thus, this factor is driving the market CAGR.

Numerous variables, including genetic predisposition, environmental triggers, and immune system disruption, are to blame for the rising frequency of ulcerative colitis and Crohn's disease. Most people with ulcerative colitis or Crohn's disease have a family history of the condition. For instance, according to a study by Hopkins Medicine, 10-15% of Crohn's disease patients had a history of the condition in their families. A family history of ulcerative colitis affects around 5-7% of people with the condition. Several government agencies are raising public awareness of these illnesses by teaching the public about these diseases' symptoms, diagnoses, and treatments. Therefore, growing consumer knowledge of various treatment alternatives and rising illness detection rates in emerging nations would boost Inflammatory Bowel Disease treatment market revenue expansion.

Figure1:  burden of Inflammatory Bowel Disease TreatmentSource: Secondary Research, Primary Research, MRFR Database and Analyst Review

Some of the reasons driving the growth of the Inflammatory Bowel Crohn's disease and ulcerative colitis are becoming more common, and there is a growing awareness of the ailment. As a result, several important industrial firms are concentrating on R&D and looking into new prospective candidates for treating IBD. For instance, more than 145 clinical trials are ongoing for Crohn's disease and ulcerative colitis, according to ClinicalTrials.gov. Phases 3 and 4 of clinical trials are where most compounds are. Thus, it is anticipated that this aspect will accelerate Inflammatory Bowel Disease treatment market revenue.

Inflammatory Bowel Disease Treatment Market Segment Insights

Inflammatory Bowel Disease Treatment Drug Class Insights

Based on drug class, the market of inflammatory bowel disease treatment segments includes TNF inhibitors, amino salicylates, immunomodulators and corticosteroids. The TNF inhibitors segment held the majority share in 2022 market data. The high rate of TNF inhibitor prescriptions for the treatment of IBD and growing consumer knowledge of TNF inhibitors are both responsible for the significant category share. Humira, Remicade, Simponi, Cimzia, and other biosimilars are important TNF inhibitors used to treat inflammatory illnesses. However, the loss of patent protection for TNF inhibitors may impede market expansion in the upcoming years. Additionally, businesses are concentrating on label expansion of already-available items to increase their market reach.

Inflammatory Bowel Disease Treatment Disease indication Insights

The inflammatory bowel disease treatment market segmentation, based on disease indication, includes ulcerative colitis and crohn's disease. The Crohn’s disease segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. The category is expanding due to factors such as the rising prevalence of the disorder, the high expense of treating Crohn's disease, and the number of prescribed biologics. Additionally, the existence of promising pipeline candidates anticipated to debut in the next years is anticipated to support segment development.

For instance, Skyrizi IV was approved by the European Commission in November 2022 to treat moderate to severe Crohn's disease.

Figure 2:  Inflammatory Bowel Disease Treatment Market, by Disease Indication, 2023 & 2032 (USD Billion)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Inflammatory Bowel Disease Treatment Distribution Channel Insights

Based on distribution channels, the Inflammatory Bowel Disease treatment market data includes Hospital pharmacies, Retail pharmacies, and online pharmacies. The category is anticipated to develop as a result of factors like increased hospitalization rates, an increase in the severity of IBD, and a rise in the elderly population. The industry is also anticipated to rise due to improved reimbursement policies in established and emerging nations that cover expensive IBD treatment solutions. On the other side, the market for treating Inflammatory Bowel Disease treatment was dominated by the retail pharmacy sector, which had the second-largest share.

Inflammatory Bowel Disease Treatment End-user Insights

Based on End-user, the Inflammatory Bowel Disease treatment industry includes Hospitals & Clinics and others.

News: A group at the Korea Advanced Institute of Science and Technology (KAIST) led by Hee-Seung Lee and Sangyong Jon has now created a novel strategy for a drug that may be administered orally that targets the inflammatory regions in the gastrointestinal tract while limiting systemic effects. A South Korean research group has revealed a brand-new treatment strategy in Angewandte Chemie. It is based on nanoparticles that imitate the glycocalyx, a particular layer of carbohydrates found on inflamed bowel cells, which causes anti-inflammatory actions in the sick areas of the intestine. Anti-inflammatory drugs such as corticosteroids, immunomodulators, and 5-aminosalicylic acid (5-ASA) are used in current therapy to lessen symptoms. Due to its significant adverse effects, such as an elevated risk of infection brought on by immunosuppression, their prolonged usage is not advised.

Inflammatory Bowel Disease Treatment Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. North America Inflammatory Bowel Disease treatment market accounted for USD 6.36 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. North America dominated the worldwide market for the treatment of Inflammatory Bowel Disease treatment as a result of the existence of several powerful market players and the numerous strategic initiatives they carried out there.

 Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3:  INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SHARE BY REGION 2022 (%)Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

By geography, Europe's market of Inflammatory Bowel Disease treatment had the second-largest market for Inflammatory Bowel Disease treatment in 2021. Due to the increased frequency of Inflammatory Bowel Disease treatment, alcohol consumption, bad lifestyle choices, and anxiety and depression among adults, the European market is anticipated to rise steadily throughout the projected period. Moreover, the U.K. Inflammatory Bowel Disease treatment held the largest market share, and the Germany Inflammatory Bowel Disease treatment was the fastest-growing market in the region.

Over the projection period, the Asia Pacific Inflammatory Bowel Disease treatment is expected to see the fastest growth. Some key reasons driving market expansion in the upcoming years include an aging population, a high chance of getting inflammatory illnesses, an increase in the incidence of inflammatory bowel disorders, and better healthcare policies in the area. Further, the China Inflammatory Bowel Disease treatment held the largest market share, and the India Inflammatory Bowel Disease treatment was the fastest-growing market in the region.

Inflammatory Bowel Disease Treatment Key Market Players & Competitive Insights

Major industry companies are investing a lot of money in R&D to expand their product offerings, which will spur further market expansion for Inflammatory Bowel Disease treatment. With significant industry changes, including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. To grow and remain in a market that is becoming increasingly competitive, Inflammatory Bowel Disease treatment industry competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the producers' main business methods in the Inflammatory Bowel Disease treatment industry to benefit customers and increase the market sector. The Inflammatory Bowel Disease treatment industry has recently given medicine some of the most important advantages. In the Inflammatory Bowel Disease treatment market, major players such as Abbott Laboratories, Valeant Pharmaceuticals International, Novartis AG, Janssen Biotech, Inc., Alkem Laboratories Limited, AbbVie, Inc., UCB Inc, Takeda Pharmaceutical Company Limited, Biogen Inc., Pfizer Inc., Allergan plc.

An American biopharmaceutical business called AbbVie was established in 2013. It began as an Abbott Laboratories spin-off. RINVOQ, a Janus kinase inhibitor, was given U.S. FDA clearance by AbbVie, Inc. in March 2022 to treat ulcerative colitis. Additionally, AbbVie, Inc. declared the completion of its purchase of Allergan in May 2020, which is anticipated to increase the company's pharmaceutical line for the treatment of IBD.

Athos Therapeutics Inc. is developing Precision Therapeutics based on artificial intelligence for people with Inflammatory Bowel Disease treatment, other inflammatory disorders, and cancer. To further precision medicine for IBD and ulcerative colitis, Athos Therapeutics announced intentions for a research partnership with Lahey Hospital and Medical Center in Burlington, Massachusetts, in July 2022.

Key Companies in the Inflammatory Bowel Disease Treatment market include

• Abbott Laboratories


• Valeant Pharmaceuticals International


• Novartis AG


• Janssen Biotech, Inc.


• Alkem Laboratories Limited


• AbbVie, Inc.


• UCB Inc


• Takeda Pharmaceutical Company Limited


• Biogen Inc.


• Pfizer Inc.


• Allergan plc

Inflammatory Bowel Disease Treatment Industry Development

• August 2021 Alternative research targeting and chelating excess succinate in IBD patients was done by Yonsei University in Seoul and Ben-Gurion University of the Negev in Israel. This research may provide an alternative to biological, steroid, and antibiotic therapy for Inflammatory Bowel Disease treatment. In Phase 3 ulcerative colitis maintenance study, upadacitinib met all secondary endpoints and the primary goal of clinical remission at one year, according to AbbVie.


• March 2020 Remsima SC was introduced by Celltrion Healthcare in Europe to treat U.C. and Crohn's disease. Additionally, pipeline medications, including brazikumab, lebrikizumab, certolizumab, stasimon, and others, are anticipated to boost market expansion.

Inflammatory Bowel Disease Treatment Market Segmentation

Inflammatory Bowel Disease Treatment Drug Class Outlook

• TNF Inhibitors


• Aminosalicylates


• Immunomodulators


• Corticosteroids

Inflammatory Bowel Disease Treatment Disease Indication Outlook

• Ulcerative Colitis


• Crohn’s Disease

Inflammatory Bowel Disease Treatment Distribution Channel Outlook

• Hospital Pharmacy


• Retail Pharmacy


• Online Pharmacy

Inflammatory Bowel Disease Treatment End-User Outlook

• Hospitals and Clinics


• Others

Inflammatory Bowel Disease Regional Outlook  

• 
  

  North America

  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America